Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Copeptin Serum Level in Liver Transplant Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03587623
Recruitment Status : Recruiting
First Posted : July 16, 2018
Last Update Posted : October 12, 2018
Sponsor:
Information provided by (Responsible Party):
Beata Błaszczyk, Medical University of Warsaw

Brief Summary:
The study aim is to measure perioperative copeptin concentration in blood of liver transplant recipients and to assess whether there is a correlation between its level and hemodynamic derangement.

Condition or disease
Liver Cirrhosis Copeptin Liver Transplant

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Copeptin Serum Level in Liver Transplant Recipients
Actual Study Start Date : July 4, 2018
Estimated Primary Completion Date : July 4, 2019
Estimated Study Completion Date : September 4, 2019





Primary Outcome Measures :
  1. Serum Copeptin concentration [ Time Frame: Baseline, intraoperatively, 1,3,7,21 day postoperatively ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients undergoing liver transplant
Criteria

Inclusion Criteria:

- Patient undergoing liver transplantation

Exclusion Criteria:

  • Serum creatinine > 1,5 mg/dl
  • Retransplantation
  • Patient refusal
  • CRRT or dialysis preoperatively

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03587623


Locations
Layout table for location information
Poland
I Klinika Anestezjologii WUM Recruiting
Warsaw, Mazovian Voivodeship, Poland, 02-005
Contact: Beata Błaszczyk, MD, PhD    004822502121    klinanest1@wum.edu.pl   
Sub-Investigator: Piotr Mieszczański, MD         
Sponsors and Collaborators
Medical University of Warsaw

Layout table for additonal information
Responsible Party: Beata Błaszczyk, Principal Investigator, Medical University of Warsaw
ClinicalTrials.gov Identifier: NCT03587623     History of Changes
Other Study ID Numbers: Livercopeptin
First Posted: July 16, 2018    Key Record Dates
Last Update Posted: October 12, 2018
Last Verified: October 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Pituitary Diseases
Liver Cirrhosis
Diabetes Insipidus
Liver Diseases
Digestive System Diseases
Kidney Diseases
Urologic Diseases
Endocrine System Diseases
Arginine Vasopressin
Hemostatics
Coagulants
Vasoconstrictor Agents
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs